Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,384 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹360 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Gland Pharma's Q3 FY25 consolidated revenue was INR 1,384 crore, with EBITDA margin improving 100 bps YoY to 26%. Base business (ex-Cenexi) revenue declined 8% YoY to INR 1,012 crore due to volume degrowth in key products like Enoxaparin, partly offset by new launches. Base EBITDA margin expanded to 39% (vs 34% YoY) driven by favorable product mix and cost controls. Cenexi posted negative EBITDA of INR 31 crore, impacted by an unannounced ANSM inspection at Fontenay. Management guided for Cenexi EBITDA breakeven by Q3 FY26, pushed out from earlier Q4 FY25. New CEO Shyamakant Giri outlined priorities including ROW market focus, India expansion, and biologics CDMO partnerships. Risk: Cenexi recovery may be further delayed if regulatory issues persist or revenue ramp-up falls short.
Colored figures show movement against the previous available record.
Guidance to track
- Cenexi is expected to achieve positive EBITDA by Q3 FY26, delayed from earlier Q4 FY25 guidance due to ANSM inspection impact.
- Management targets Cenexi quarterly revenue above EUR 15 million to support EBITDA breakeven, driven by new high-speed lines.
- Collaboration with Dr. Reddy's for biologics CDMO is expected to generate incremental revenue starting next financial year (FY26).
- Planned expansion of biologics drug substance capacity by 15KL to support the Shanghai Henlius collaboration, with revenue likely from FY27-28.
Risks flagged
- Unannounced ANSM inspection at Fontenay caused production loss and corrective measures, pushing EBITDA breakeven to Q3 FY26. Further regulatory actions could delay recovery.
- Base business revenue declined 8% YoY due to volume degrowth in key products like Enoxaparin. Recovery depends on timing of shipments and new product ramp-up.
- The Saudi tender shipment was pushed out by a quarter, impacting Q3 revenue. Further delays could affect near-term ROW growth.
- Chinese players control 50-60% of Heparin API supply. While US tariffs may benefit Gland, raw material dependence on China remains a risk.
Key quotes
- We expect to recover these volumes in the coming quarters and remain optimistic about the overall trajectory of our business.
- We are estimating now third quarter FY26 could be a bit of a positive quarter.
- We have a constant flow of opportunities that we are looking at. What is especially encouraging in the last quarter is that we finalized the validation batches for two products that will move in Q1 into commercial production.
Research modules